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Abstract
The United States (US) has a complex healthcare system with a mix of public, private, nonprofit, and for-profit insurers, healthcare
institutions and organizations, and providers. Unlike other developed countries, there is not a single payer healthcare system or a
national pharmaceutical benefits scheme/plan. Despite spending over USD 10,000 per capita in healthcare, the US is among the worst
performers compared to other developed countries in outcomes including life expectancy at birth, infant mortality, safety during
childbirth, and unmanaged chronic conditions (e.g., asthma, diabetes). Primary care is delivered by physicians and advanced practice
providers (i.e., nurse practitioners and physician assistants) in a variety of settings including large health systems, federally qualified
health centers or free clinics that provide care to the underserved, or specific facilities for veterans or American Indian and Alaska
native peoples. Since 2010, primary care delivery has shifted toward providing patient-centered, coordinated, comprehensive care
focused on providing proactive, rather than reactive, population health management, and on the quality, versus volume, of care.
Community pharmacy comprises a mix of independently owned, chain, supermarket and mass merchant pharmacies. Community
pharmacies provide services such as immunizations, medication therapy management, medication packaging, medication
synchronization, point-of-care testing and, in specific states where legislation has been passed, hormonal contraception, opioid
reversal agents, and smoking cessation services. There has been criticism regarding the lack of standard terminology for services such
as medication synchronization and medication therapy management, their components and how they should be provided, which
hampers comparability across studies. One of the main challenges for pharmacists in the US is the lack of provider status at the federal
level. This means that pharmacists are not allowed to use existing fee-for-service health insurance billing codes to receive
reimbursement for non-dispensing services. In addition, despite there being regulatory infrastructure in multiple states, the extent of
service implementation is either low or unknown. Research found that pharmacists face numerous barriers when providing some of
these services. State fragmentation and the lack of a single pharmacy organization and vision for the profession are additional
challenges.
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HEALTHCARE DELIVERY IN THE US
The United States (US) has a population of approximately
330 million people from diverse backgrounds and cultures.1
The US spends nearly 17% of its gross domestic product
(GDP) on healthcare at over USD 10,000 per capita, which is
twice the average compared to other developed countries.2
Yet, the US is among the worst performers compared to
other developed countries in key health outcomes,
including life expectancy at birth, infant mortality, safety
during childbirth, and unmanaged chronic conditions like
asthma and diabetes.
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The US is one of the few developed countries without
universal healthcare coverage; it does not have a single
payer healthcare system or a national pharmaceutical
benefits scheme/plan. The healthcare system includes a
mix of public, private, nonprofit, and for-profit insurers,
healthcare institutions and organizations, and providers.
Modern healthcare coverage in the US began in the 1920s
when hospitals offered pre-paid services to individuals, and
a group of teachers in Dallas, Texas joined the first
employer-sponsored hospitalization plan in 1929. During
World War II, employer-sponsored health insurance
became more popular in response to freezes on wage
increases by the federal government. Employers could
provide non-wage benefits (e.g., health insurance, sick
leave) which were considered tax exempt, instead of
increasing wages. Today, half of Americans receive health
insurance coverage from their employer.3
The first major step toward government-sponsored
healthcare coverage came with an amendment to the
Social Security Act in 1965, which created Medicare and
Medicaid and provides healthcare benefits to select groups
of individuals. Medicare covers individuals age 65 years or
older, those under age 65 who are disabled, and select
disease states (e.g., end-stage renal disease), while
Medicaid applies to eligible low-income individuals,
pregnant women, children under 18 years of age, and those
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with disabilities. In 1997, federal legislation increased the
number of children covered with the Children’s Health
Insurance Programs, also administered via Medicaid.
Importantly, each state is responsible for administering
Medicaid programs and providing a safety net for those
who do not qualify for Medicaid, and this state-level
administration results in different coverage across states.
Medicare Part D is the federal-government program
initiated in 2006 that subsidizes the costs of prescription
drug coverage to Medicare enrollees via contracts with
numerous insurance companies (Part D sponsors), and it
was enacted via the Medicare Prescription Drug,
Improvement, and Modernization Act in 2003.4 While
optional, all states currently provide coverage for
outpatient prescription drugs to categorically eligible
individuals, as well as most other enrollees.5
Yet, given the nearly 46.5 million individuals that remained
uninsured in 2010, the Patient Protection and Affordable
Care Act (ACA, also known as “Obama care”) was passed in
2010 and implemented in 2014 to expand healthcare
coverage.6 The ACA created health insurance exchanges, or
marketplaces, where low- and middle-income individuals
could purchase their own insurance and receive
government subsidies to offset the costs. States also
received additional federal funding if they agreed to
expand eligibility for Medicaid; however, not all states took
advantage of this. Young people can also remain covered
under their parent’s plan until age 26.7 Debate continues in
the US regarding the role of government in providing
healthcare insurance.
Demand on the US healthcare system has led to a
significant expansion of jobs in healthcare. Between 2006
and 2016, jobs in healthcare settings increased by 20%,
compared to only 3% job growth in the general economy.8
The job growth has been primarily in personal care aides,
registered nurses, nursing assistants, and home health
aides, likely due to the rapidly aging population in the US.
Physician shortages, especially in primary care, are a key
issue in the US with a projected shortage between 21,400
and 55,200 by 2033.9 In response, there has been a sharp
increase in the number of nurse practitioners in the US,
which are now approaching 300,000.10 Likewise, the
number of physician assistants is increasing with expected
job growth of 30% through 2028. With full prescribing
privileges (unlike pharmacists), nurse practitioners and
physician assistants are well positioned to fill gaps in the US
primary care system.
The projected outlook for pharmacists in the US is widely
debated. The optimistic outlook suggests that evolving
practice roles for pharmacists will create new opportunities
for employment in direct patient care roles. This is evident
by the increased demand for specialty trained pharmacists
to work in health systems and clinics.11 On the other hand,
there is no doubt that the exponential growth in the
number of graduating pharmacists provides increased
supply and that overall demand for pharmacists is
shrinking, especially in the traditional community pharmacy
sector. This can largely be due to losses of revenue,
attributable to decline in reimbursement for dispensing
medications and lack of significant reimbursement for
clinical services. The US Bureau of Labor Statistics projects
0% growth for pharmacists through the year 2028.12 The

surplus of US pharmacists is largely related to the 38%
increase in the number of pharmacy schools and 48%
increase in the number of graduates over the past decade.
It is possible, however, that this issue may correct itself as
the mean number of applications per pharmacy school has
declined over 50% in the past decade.13
Primary care in the US
Primary care in the US is delivered by three medical
specialties: family medicine, general internal medicine, and
general pediatrics. Additionally, other non-physician
primary care providers (e.g., registered nurses, nurse
practitioners, physician assistants, pharmacists) provide
care alongside physicians.14,15 To further the objective of
improving primary care, the American Academy of Family
Physicians proposed the Health Care for All framework
whose goal is to “ensure healthcare coverage for everyone
in the United States through a foundation of
comprehensive and longitudinal primary care”.16
Since the passage of the ACA, there has been a shift toward
transforming primary care to provide patient-centered,
coordinated, comprehensive care focused on providing
proactive, rather than reactive, population health
management. One such approach is the patient-centered
medical home (PCMH) which facilitates partnerships
between individual patients, their families, and their
personal physicians.17 The main principles of the PCMH
outlined by the Agency for Healthcare Research and Quality
are that: 1) it provides comprehensive care by a
multidisciplinary team being accountable for meeting
physical and mental healthcare needs; 2) it is patientcentered, in that it considers the patients’ and their
families’ unique needs, culture, values and preferences,
and it promotes patients’ involvement in their care and
disease management; 3) care is coordinated or integrated
across specialty care, hospitals, home healthcare, and
community services and supports, especially during
transitions of care; 4) it offers accessible services wherein
urgent needs are addressed, hours of operation are
expanded, a member of the care team is available
electronically or via the telephone, and there are
alternative methods of communication such as email and
telephone; 5) it is committed to quality and safety by
engaging in performance measurement and continuous
quality improvement, and adopting a population health
management approach to care. In the PCMH model,
payment recognizes patient-centered care management
work beyond face-to-face visits, supports the use of health
information technology for quality improvement,
recognizes remote monitoring of clinical data using
technology, allows additional payments for achieving
quality improvement measures, and allows practices to
share in savings generated from reduced hospitalizations.18
Another approach to improve primary care delivery is
through accountable care organizations (ACOs), which are
groups of providers who share the joint responsibility for
the costs and quality of care provided to an assigned group
of Medicare patients.19 In addition to receiving
reimbursement based on the traditional fee-for-service
model, ACOs are eligible to voluntarily participate in the
Centers for Medicare & Medicaid Services (CMS) Shared
Savings Program, a program that focuses on value and

www.pharmacypractice.org (eISSN: 1886-3655 ISSN: 1885-642X)

2

Salgado TM, Rosenthal MM, Coe AB, Kaefer TN, Dixon DL, Farris KB. Primary healthcare policy and vision for community
pharmacy and pharmacists in the United States. Pharmacy Practice 2020 Jul-Sep;18(3):2160.
https://doi.org/10.18549/PharmPract.2020.3.2160

patient outcomes, rather than the number of encounters or
procedures. As of January 1, 2020, there were 517 ACOs
participating in the Shared Savings Program that provided
care to 11.2 million (16.5%) Medicare beneficiaries.20
The PCMH and ACO are complementary approaches to
reformed care delivery. Despite notable progress in the
past years, not all primary care in the US is provided
through PCMH and ACOs. There are still many independent
primary care physician practices and large health systems
that do not provide care by either of these models.
Finally, primary care is also provided in an array of other
clinics focused on specific populations. Federally qualified
health centers (FQHCs) are community-based health
centers that provide primary care in underserved areas.21
The Indian Health Service provides care in federal facilities
to American Indian and Alaska native peoples.22 As well,
the Veterans Health Administration serves about 9 million
veterans yearly.23 Each of these systems is funded by the
federal government. In addition, many communities also
have free clinics that use volunteer/staff to provide
healthcare services to disadvantaged individuals.24
In summary, primary care is provided in many different
types of clinics and the providers are paid from numerous
sources. Three medical specialties, advanced practice
providers, and other clinicians support the delivery of
primary care, and there is no single model of practice or
reimbursement.
COMMUNITY PHARMACY IN THE US
Community pharmacy in the US is comprised of a number
of sub-types of practice settings including independent,
traditional chain, supermarket, and mass merchant
pharmacies (Figure 1). The National Community
Pharmacists Association (NCPA) reported that there were
61,800 community pharmacies in the US in 2018.25 Of the
314,300 pharmacists in the US in 2018, more than 135,000
(43%) worked as community pharmacists.26 Substantial
differences in the number of pharmacies by county and
region of the country have been identified with counties
possessing the highest density of pharmacies per
population having nearly three times as many pharmacies
compared to those with the lowest density of
pharmacies.27 Thus, where a patient lives in the US greatly
impacts their access to community pharmacy services.

Some pharmacies are able to generate revenue via clinical
services (described below), but the primary business model
for community pharmacies continues to focus on
dispensing prescription medications to patients. In 2019,
almost 3.8 billion prescriptions were filled in US
pharmacies.28 While the majority (about 1.9 billion) were
paid for by commercial insurers, which includes some
government programs like the Children’s Health Insurance
Program, Veterans Administration, and Indian Health
Service, approximately 1.67 billion prescriptions were paid
for, at least in part, by either Medicare or Medicaid, with
patients being responsible for a co-payment.28 Payers’
coverage of prescriptions varies greatly across community
pharmacy sub-type.25 In 2019, prescription dispensing
revenues in the US reached a record USD 446 billion, with
the top seven dispensing pharmacies (i.e., CVS Health,
Walgreens Boots Alliance, Cigna, UnitedHealth Group,
Walmart, Kroger, and Rite Aid) accounting for about 70% of
the market.29 Detailed data from 2018 showed that
independent pharmacies represented a USD 75.8 billion in
prescription revenue, while CVS represented USD 102
billion, followed by the Walgreens Boots Alliance at USD
74.4 billion, Walmart at USD 20.9 billion, Kroger at USD
13.4 billion, and Costco at just USD 2.6 billion.30
In the US, medications are typically dispensed inside
prescription vials or bottles that are filled at the pharmacy
from bulk containers, rather than in individual blisters
within boxes sold by the pharmaceutical industry, as is the
case in Europe. Thus, the primary role of pharmacy
technicians is to fill prescriptions and label medications in
prescription bottles that the pharmacist then verifies. A
growing body of literature supports expanding the role of
technicians to administrative roles such as managing
patient
appointments,
collecting
comprehensive
medication histories, and collecting clinical data to be
reported to the pharmacist.31 The Pharmacy Technicians
Certification Board provides national standards for
technicians. Regulations and requirements for certification,
registration, and licensure vary by state. To date, 24 states
require pharmacy technicians to attain national
certification, either as a requirement to be registered or
licensed, or to perform certain duties.32
Policy considerations affecting community pharmacy in
the US
One of the most significant barriers to advancing

Figure 1. Sub-types of community pharmacies in the US and estimates for each type based on NCPA data
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community pharmacy practice in the US is the current
payment structure. When the Social Security Act was
passed in 1965, pharmacists were omitted from the
definition of healthcare providers, resulting in pharmacists
not being able to be paid by the Federal government for
most services under Medicare Part B (i.e., while Medicare
Part A covers hospital care, Medicare Part B covers services
provided by physicians and other providers in outpatient
settings). Because other payers generally follow Medicare
payment policies, there are limited opportunities for
pharmacists to receive reimbursement from public, private
or commercial payers. Being recognized by CMS as a
provider would enable pharmacists to use existing fee-forservice health insurance billing codes when they provide
non-dispensing services. Some exceptions exist for specific
services provided to Medicare beneficiaries in Part D
programs, such as medication therapy management (MTM)
and immunizations.

to-face access to a pharmacist, and creating a
comprehensive medication list. Additional enhanced
services provided by select pharmacies comprise: 24-hour
emergency services, collection of vital signs, home
delivery/home visits, tobacco cessation program, durable
medical equipment, point-of-care testing, long-acting
injections, naloxone dispensing, nutritional counseling, and
specialty medication compounding.39 To the best of our
knowledge, no public information exists regarding the
percentage of pharmacies providing each of the services
and the reimbursement rates negotiated (if any) for each
service across states. Several challenges were reported by
pharmacists in the North Carolina CPESN offering
medication management services related with initiating
services, accessing internal and external information,
documenting, among others. This same study found that 73
(59.3%) of the 123 participating pharmacies did not
complete service requirements within the first 3 months.40

Achieving this objective requires working with the federal
government to develop and pass legislation to add
pharmacists to its list of providers.33 To that end, 11
pharmacy organizations and other stakeholders are
working together towards achieving provider status for
pharmacists and studying possible options for legislative
language that are primarily focused on amending the Social
Security Act.34 Given the myriad pharmacy organizations in
the US prioritizing their own agenda (e.g., American
Pharmacists Association, American College of Clinical
Pharmacy, American Society of Health-System Pharmacists,
Academy of Managed Care Pharmacy, American Society of
Consultant Pharmacists, among others), having a unified
voice for the pharmacy profession is a challenge. The fact
that 11 organizations have united efforts to advocate for
provider status underscores the importance of such
legislation for the profession.

In 2019, the Community Pharmacy Foundation and CPESN
partnered to fund the Flip the Pharmacy initiative which
aims to transform community pharmacy practice, moving
away from point-in-time and prescription-level to
longitudinal and patient-level care processes and business
models.41 Six transformation domains comprise the
initiative, namely: leveraging the appointment-based
model, improving patient follow-up and monitoring,
developing new roles for non-pharmacist support staff,
optimizing the utilization of technology and electronic care
plans, establishing working relationships with other care
team members, and developing the business model and
42
expressing value. The initiative is currently underway,
thus limited evidence regarding its impact on community
pharmacy processes, volume and payment of services, or
patient outcomes exists.43 The ultimate goal is to gather
evidence of the contribution of community pharmacists to
improved patient care to serve as a means to negotiate
reimbursement for pharmacist services with payers.

Passing such federal legislation is likely to take considerable
time, and several individual states (e.g., California,
Washington) have passed provider status legislation for
pharmacists, though they continue work on how these
statutes will be implemented.35,36 Achieving provider status
at the state-level, in theory, may allow pharmacists to
negotiate reimbursement for services directly with
insurance companies; however, payment may still not
follow provider status recognition at the state level.
Community Pharmacy Enhanced Services Network
The Community Pharmacy Enhanced Services Network
(CPESN) is a clinically integrated network of community
pharmacies (mostly independent), that resulted from the
expansion of the Community Care of North Carolina in 2014
with funding from a 3-year grant by the Centers for
Medicare and Medicaid Innovation (CMMI). The goal was
to provide a structure for community pharmacies to expand
primary care efforts, as well as a means to negotiate
reimbursement for services with payers as a group.37,38 This
model has now spread to 44 states and includes 2,700
community pharmacies that offer enhanced services for
high-risk patients. The core services that pharmacists are
required to offer to be a part of the network include
medication reconciliation, medication synchronization,
immunizations, comprehensive medication reviews, face-

Pharmacy education and training in the US
Since 2000, the recognized professional degree that can be
obtained from schools of pharmacy in the US is the
Pharm.D. (doctoral degree). However, there remain a
significant number of practicing pharmacists who were not
trained at the doctoral level and have bachelor’s or
master’s degrees.44 The 2016 American Council on
Pharmaceutical Education’s set of educational standards
were designed to ensure that all graduating pharmacists
were prepared to contribute meaningfully to patientcentered care and interdisciplinary team practice, use
evidence-based practice, apply quality improvement
strategies, and utilize informatics.44 While communitybased pharmacy residencies are not currently required, the
number of such residencies has grown in the last 20 years
to more than 130 accredited post-graduate year 1 (PGY1)
programs.45 However, this growth has not kept pace with
demand by student pharmacists or professional
organizations such as the American College of Clinical
Pharmacy, which previously advocated that starting in 2020
all pharmacists involved in direct patient care complete an
accredited residency.45
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Integration of community pharmacy and primary care
Pharmacists are integrated into primary care in a number
of important ways, which continue to evolve over time. In
support of better coordination between community
pharmacy and primary care, the Centers for Diseases
Control and Prevention (CDC) Division for Heart Disease
and Stroke Prevention developed a practitioner and a
pharmacist guide for “Creating Community-Clinical Linkages
Between Community Pharmacists and Physicians” in
collaboration with the American Pharmacists Association
and the American Medical Association.46,47 Communityclinical linkages are defined as connections between the
community, clinics, and other settings where primary care
is provided to improve population health.46 The pharmacist
guide provides a framework called LINKAGE outlining how
community pharmacists and physicians can develop
community-clinical linkages.47 Suggested activities to be
performed by both parties as part of these linkages include:
pharmacists conducting health assessments and referring
patients to physicians for diagnosis or treatment;
pharmacists triaging patients with medication-related
problems or new/worsened health conditions into primary
care; and physicians referring patients to pharmacists for
medication and chronic conditions management.47
One way for community pharmacists to provide services
and be reimbursed is by extending beyond the walls of the
pharmacy and establish collaborations with primary care
clinics. An example of such a model is pharmacists from an
independent community pharmacy in the state of North
Carolina providing services at an independent primary care
48,49
clinic three days a week.
Over and above improving
patient outcomes, this service also gained the clinic an
additional USD 16,920 in annual reimbursement.49
Pharmacists provide chronic care management services
(i.e., services aiming to improve health outcomes by
enhancing care coordination for patients with multiple
chronic conditions) to Medicare beneficiaries, reimbursable
since January 2015 via the Medicare fee-for-service
program.50 The goal is to help the primary clinic achieve the
quality measures set by CMS, while also arranging a way for
both parties (physician and pharmacists) to be reimbursed,

even if billing is under the physician’s fee schedule. This
model is by no means widespread in the US and requires
collaboration with a provider.50
Primary care is also moving inside pharmacies. Several
community pharmacy chains and mass merchants have
opened walk-in clinics inside their stores as a means to
increase access to care. For example, CVS has co-located
Minute Clinics that provide walk-in care for minor illnesses,
minor injuries, skin conditions, travel health, vaccinations
and injections, wellness and physicals, women’s services,
and screenings and monitoring. Cost of services can be
covered by insurance plans or paid out-of-pocket.
Treatment for minor illnesses, minor injuries, skin
conditions, wellness and physicals, and screenings and
monitoring cost between USD 99-139/visit; cost for travel
health related items ranges between USD 59-142; women’s
services cost between USD 59-250; and vaccinations and
injection administration between USD 50-250.51 Care is
provided by nurse practitioners and physician assistants
(not pharmacists) to both adults and children.52,53 The CEO
of CVS Health has publicly stated that “retailization of
healthcare” will continue to evolve, with service
convenience being a top priority.54 Walgreens had a similar
arrangement up until 2019, but decided to outsource the
service to VillageMD, a group of primary care physicians, in
July 2020. They plan to open 500-700 “Village Medical at
Walgreens” physician-led primary care clinics in more than
30 US markets in the next five years. The press release
mentions that pharmacists will be integrated as a critical
member of the VillageMD’s multi-disciplinary team, but no
further details are provided.55
Pharmacist prescriptive authority
In the US, pharmacists who are able to prescribe, monitor,
and adjust medications independent of or in collaboration
with physicians can generally provide associated clinical
services. The National Alliance of State Pharmacy
Associations (NASPA) is a trade association that tracks
pharmacy legislation and regulations across all 50 states
and the District of Columbia.56 NASPA and the Idaho State
Board of Pharmacy proposed a framework to characterize

Figure 2. Summary of available practice models adopted by states that allow pharmacists to prescribe in the United States
(CPAs, collaborative practice agreements)
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existing models of pharmacist prescriptive authority along a
continuum from most restrictive to least restrictive (Figure
2).57 At present, 49 states and the District of Columbia have
passed legislation that allows pharmacists to prescribe
medications under CPAs, standing orders, or statewide
protocols.

dissemination across the country, scale up of services is
maximized. For example, reports demonstrate chain
pharmacies positioning themselves to meet demand for
convenience in offering immunization services.62 However,
work in a busy chain pharmacy can lead to pharmacist burn
out, which in turn compromises patient safety.63,64

In a collaborative prescribing model, pharmacists and
prescribers create formal relationships through the
establishment of collaborative practice agreements (CPAs)
wherein the latter grant prescriptive authority to the
former.58,59 CPAs can be patient-specific (i.e., individual
patients or a collaborating prescriber’s patient panel) or
population-specific (i.e., categories of patients). While
population-specific CPAs are commonly used for acute care
(e.g., treatment of influenza in patients with certain
characteristics that do not meet criteria for automatic
referral), both patient- and population-specific CPAs are
established for chronic disease management (e.g.,
diabetes, hypertension, hyperlipidemia, asthma).57

The services described below represent the mainstream
services that pharmacists currently provide and, in
particular circumstances, for which they can obtain
reimbursement (Table 1). Due in part to the fragmented
nature of the healthcare system in the US, it is not currently
possible to report the extent to which these services are
provided. Existing evidence usually derives from research
studies that academics conduct with data obtained from
either local Boards of Pharmacy or state-wide surveys, the
latter usually limited by a low response rate. More recent
reports of MTM have used Medicare Part D claims to
examine some services.

Autonomous prescribing can occur via statewide protocols
or unrestricted category-specific prescribing. In these
situations, CPAs are not required to be in place for
pharmacists to prescribe; however, pharmacists are still
responsible for coordinating care with the primary care
provider. Statewide protocols are set by an authorized
body or state government (e.g., Board of Pharmacy,
Department of Health) and allow pharmacists to prescribe
medications that are intended for preventive care or for
acute or self-limiting conditions that require a limited
process to diagnosis. The scope of statewide protocols is
generally narrow and often arises in response to a public
health crisis. Any pharmacist who fulfills the requirements
specified in the protocol is authorized to prescribe without
supervision from a collaborating physician, unlike CPAs.57
Unrestricted category-specific prescribing applies to a
limited range of medications for which no specific diagnosis
is needed. Instead of following a state-derived protocol,
states refer pharmacists to other authority documents,
such as practice guidelines, to guide prescribing.
Autonomous and collaborative prescribing supplement
each other, rather than being mutually exclusive.57
A standing order is a statewide prescription issued by a
state designated prescriber under which pharmacists are
allowed to fill a prescription to dispense a product (e.g.,
naloxone, smoking cessation products). In this model,
pharmacists are not the prescribers.
Community pharmacy services
As described above, pharmacy practice legislation varies
across all 50 states and the District of Columbia. Likewise,
reimbursement for specific services also differs at the state
level, unless reimbursement is based on federal legislation,
as is the case of services for Medicare beneficiaries. In the
US, there is a history of pharmacy services innovations, but
state fragmentation and the lack of a single payer system
and a single vision and voice for the pharmacy profession
prevent scaling these innovations at the national level.
Chain pharmacies play a pivotal role in scaling service
innovation in community pharmacy beyond dispensing
services through counseling, MTM services, and several
disease state management initiatives.60,61 Due to their

Immunizations
All 50 states and the District of Columbia have legislation
allowing pharmacists (and student pharmacist interns
operating under the supervision of the pharmacist) to
administer
immunizations.
States
allow
vaccine
administration via any of the prescribing mechanisms
described above, except one (Alabama) which only allows
vaccine administration by prescription. The types of
vaccines that pharmacists can administer and the minimum
age of patients to whom they are allowed to administer
also vary across states. While some allow any vaccine to be
administered to any patient regardless of age, others do
not allow pharmacists to administer certain vaccines (e.g.,
human papillomavirus vaccine) or restrict administration to
adults or children older than a certain age.65 Immunization
administration in some states also extends to CDCrecommended travel vaccinations. As of June 2020, six
states allowed pharmacy technicians who completed
immunization certificate training to administer vaccines
under the direct supervision of a certified pharmacist.65
The 2019 National Pharmacist Workforce Study reported
that 90% of community pharmacists administered
vaccines.66 In Westrick et al.’s study of a nationally
representative sample of 292 community pharmacies, 80%
reported that they had provided immunization services in
2016, the most common vaccines being influenza, herpes
zoster, pneumococcal 13-valent conjugate (PCV13) and
pneumococcal polysaccharide (PPSV23).67 Pharmacy-based
immunization services have been associated with an
increase in the likelihood of being immunized.68 As an
example, influenza vaccinations dispensed in community
pharmacies increased from 3.2 to 20.9 million between
2007 and 2013.69
In order to bill for immunization administration,
pharmacies need to contract with the appropriate payers
(i.e., pharmacy benefits managers, Medicare, Medicaid,
third-party medical plans). Pharmacies bill for both the
product and the administration service. Administration fees
vary between USD 15 and USD 40.70 Additionally,
pharmacies can charge customers or private employers
with whom they contract directly. The average direct costs
paid per adult vaccination were shown to be lower in
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Table 1. Pharmacist services available in the community pharmacy setting.
Service/Activity
Availability status (date)

Regulation
level
State

Reimbursement

Immunizations

 All 50 states and the District of Columbia (Jun. 2020)
 1 state (Alabama) only by prescription (Jun. 2020)
 6 states allow pharmacy technicians with required
training to administer vaccines under the supervision
of a certified pharmacist (Jun. 2020)

Medication Therapy
Management (MTM) program

 All 649 Medicare Part D contracts use pharmacists to
provide MTM (2019)

Federal

Medication packaging

 Implementation status unknown

N/A

Medication synchronization

 22,000 community pharmacies (2015)

N/A

Hormonal contraception
prescribing
Point-of-care (POC) testing

 9 states and the District of Columbia (Dec. 2019)

State

 Via contract with the appropriate
payers (i.e., pharmacy benefits
managers, Medicare, Medicaid, thirdparty medical plans)
 Bill payers for both the vaccine and
administration service (varies
between USD 15 - 40) or paid by
patients out-of-pocket
 Reimbursement provided by CMS
 Billing in 15-minute increments using
current procedural technology codes
 Paid by customers out-of-pocket or
offered as part of a medication
synchronization program
 No reimbursement. MTM billing
codes apply if offered as part of the
service
 Reimbursement varies by state

 All 50 states and the District of Columbia - for
approved tests with pharmacy CLIA waiver from CMS
(1988)
 All 50 states and the District of Columbia (Jan. 2019)
o
17 states and the District of Columbia - statewide
protocol/pharmacist prescribing (Jan. 2019)
o
12 states - statewide standing order (Jan. 2019)
o
4 states - dispense without a prescription (Jan.
2019)
o
17 states - standing order (Jan. 2019)

Federal

 Paid by customers out-of-pocket

State

 Variable out-of-pocket costs
depending on the patient’s health
insurance
 Pharmacist counseling not
reimbursable

 37 states (Nov. 2019)
o
12 states - statutes or regulations allowing
pharmacists to prescribe (Nov. 2019)
o
17 states - prescribe under population-based
CPAs (Nov. 2019)
o
7 states - prescribe via autonomous prescribing
(Nov. 2019)
o
1 state - independent prescribing (Nov. 2019)

State

 Reimbursement varies by state

Naloxone prescribing or
dispensing

Tobacco cessation aid
prescribing

pharmacies compared with other medical settings, likely
because in medical settings additional billing codes can be
applied (e.g., billing codes covering patient counseling).71
Medication therapy management
MTM is a service included in Medicare Part D plans that
aims at improving medication use and reducing the risk of
adverse events in eligible Medicare beneficiaries.72 MTM
includes five core elements: 1) comprehensive medication
review (CMR); 2) provision of a personal medication record;
3) construction of a medication-related action plan
consisting of a list of actions for patients to track progress
for self-management; 4) intervention to address
medication-related problems or referral to a physician or
other healthcare professional; and 5) documentation of
MTM services and follow-up visit.73,74 Part D plans are
required to provide and automatically enroll in their MTM
programs beneficiaries who meet pre-specified CMS
criteria, namely: having multiple chronic diseases, taking
multiple Part D medications, and being likely to incur
annual Part D medication costs that meet or exceed a
certain threshold every year (e.g., USD 4,044 in 2019).75
However, 27% of MTM programs in 2019 used expanded
eligibility requirements beyond the minimum required by
CMS.76 MTM services may be provided by pharmacists or
other healthcare professionals. For example, of the 649

Part D contracts with an approved MTM program in 2019,
100% used pharmacists to provide MTM services, 74% used
a registered nurse, 24.5% a physician, and 15.1% a
physician assistant (multiple selections were allowed, thus
categories were not mutually exclusive). Beneficiary
enrollment into MTM programs should be at least quarterly
(47.1% of plans in 2019), but could also be every other
month, monthly, weekly or daily. Eligible beneficiaries are
mainly identified via medication claims data.76
The CMR is a core element of MTM and it consists of an “an
interactive person-to-person or telehealth medication
review and consultation conducted in real-time between
the patient or other authorized individual, such as
prescriber or caregiver, and the pharmacist or other
qualified provider and is designed to improve patients’
knowledge of their prescriptions, over-the-counter (OTC)
medications, herbal therapies and dietary supplements,
identify and address problems or concerns that patients
may have, and empower patients to self-manage their
medications and their health conditions”. Part D sponsors
are required to provide a CMR at least annually or targeted
medication reviews (TMR) quarterly. TMRs are shorter
duration medication reviews to assess medication use,
monitor unresolved issues, identify new drug therapy
problems, and assess whether beneficiaries experienced a
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transition of care. CMR delivery method can be face-toface, over the phone or through telehealth.76 The benefits
from obtaining a CMR include the identification of
effectiveness and safety issues with prescribed
medications, as well as identification of less expensive
alternative medications for patients.77 Despite the benefits
of CMRs, the uptake of the service is low – less than 20% of
eligible Medicare beneficiaries in 2013 and 2014 received
the service –, either because patients are unaware of it or
because they perceive it as unnecessary.77-79 Data from the
2019 National Pharmacist Workforce Study indicated that
66.7% of respondents provided MTM services.66
Additionally, analyses of Medicare claims data from 2014
revealed that community pharmacies provided only 22% of
the CMRs, with the remainder provided by either other
types of pharmacists or other professionals.80 In 2018, the
CDC launched a statewide initiative focused on
implementing and evaluating evidence-based strategies to
manage diabetes and prevent or delay onset of type 2
diabetes in high-burden populations and communities, and
one of the strategies proposed is to expand MTM services
provided by pharmacists to patients with diabetes.81
The effectiveness of MTM services remains a contested
topic because of heterogeneity of previous studies’
populations, settings, and outcomes.82 In addition,
contemporary MTM definitions found in the professional
literature differed from the early definition in the
regulatory reference, making meaningful evaluations over
time difficult.83
Reimbursement to pharmacists (and other professionals)
rendering MTM services is provided by CMS. Billing is in 15minute increments using current procedural technology
codes (specific codes used for medical billing). The initial
15-min face-to-face assessment is reimbursed at a rate of
USD 50 and is covered once a year per provider per
beneficiary. Follow-up assessments of 15-minute
increments are reimbursed at a rate of USD 25 and
providers can bill up to seven times in a year. Additional 15minute increments to the two previous codes can be billed
up to four times per provider per beneficiary per date of
service at a rate of USD 10.84 Lack of standardization for
documentation and billing is an important limiting factor of
MTM programs.85 Another potentially contested aspect is
the effectiveness of a CMR without access to the electronic
health record (EHR).
Medication adherence
Similar to other countries, community pharmacists in the
US offer services aimed at improving medication
adherence.86,87
Medication packaging is one such service. Packaging
interventions significantly improved medication adherence
in a meta-analysis of 52 studies.88 This study demonstrated
that interventions using blister packs compared with pill
boxes, and delivered in pharmacies compared to
interventions delivered elsewhere were significantly more
effective at improving adherence.88 It is unclear what
percentage of community pharmacies in the US offer
medication packaging services. The service is not
reimbursed by CMS or prescription insurance plans. While
some pharmacies may offer the service as part of their

medication synchronization service, others may charge an
out-of-pocket fee to customers.
Medication synchronization is a process by which a
patient's medications refill dates are aligned so that
patients only come to the pharmacy once a month. Prior to
preparing the medication, pharmacy staff call patients to
identify whether any changes to medications occurred and
to confirm what medications should be dispensed. This
contributes to a higher efficiency of the pharmacy
workflow, in addition to presenting an opportunity for
pharmacists to perform a medication review and identify
any therapeutic or compliance issues.89 As of 2015, this
service was being offered by more than 20,000 chain and
2,000 independent community pharmacies across the
country and 66.5% of participants in the National
Pharmacist Workforce Study reported that they offered the
service.66,90 However, service provision varies across
pharmacies – while some focus exclusively on the
alignment of refill dates, others conduct an appointmentbased medication synchronization where patients meet
with the pharmacist to discuss their medications, any
adherence issues, or receive MTM services.91,92
Unfortunately, the extent to which each modality occurs is
unknown and even if it were self-reported, it is legitimate
to expect response bias. The service itself is not
reimbursable but it may contribute to increased monthly
prescription volume.93 Additionally, if MTM services are
provided with medication synchronization, the pharmacy
receives reimbursement via the MTM billing mechanisms.
Retrospective analyses of the service showed that
appointment-based medication synchronization increased
the odds of being adherent by 2 to 6 times compared to
patients not enrolled in the service.94-96 Patients in a
synchronization program also presented rates of
hospitalization and emergency department visits and rates
of outpatient visits that were 9 and 3 percent lower,
compared to a control group obtained via propensity score
matching.94 However, it is unclear which components of the
service contribute to these improvements due to the lack
of a consensus definition of medication synchronization.92
Hormonal contraception
As of December 2019, nine states and the District of
Columbia had statewide authority for autonomous
pharmacist contraception prescribing.97 Each statewide
authority has different prescribing protocols, patient age
limitations, contraceptive formulations allowed (e.g., oral,
patch), and pharmacist training requirements.97 Many
included a patient self-screening assessment, blood
pressure measurement, documentation requirements, and
patient education materials in the prescribing procedure.97
Reimbursement exists on a state-by-state basis. For
example, in the state of Oregon, certified pharmacists
prescribe hormonal contraception and are reimbursed by
Medicaid and private payers at the same rate as physicians
and nurse practitioners for both the product and the
assessment.98 Since April 2019, California’s State Medicaid
program (Medi-Cal) reimburses pharmacist services
furnishing hormonal contraception at a rate of 85% of the
fee schedule for physician services.99 A time and motion
study conducted in community pharmacies in the state of
Oregon found that pharmacists spent approximately 18
minutes to screen a patient for eligibility, document the
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encounter, and provide a written prescription for
contraceptives in an uncomplicated patient.100 A
descriptive study of 391 supermarket-based pharmacies in
California and Oregon revealed that 1970 service visits
resulted in birth control prescriptions by 381 pharmacists,
95.7% of which were for the pill, 2.1% for the vaginal ring,
1.6% for a transdermal patch and 0.1% for an injectable.101
In other studies, pharmacists described time constraints,
lack of access to EHRs, lack of reimbursement, additional
training needs, and liability concerns as potential barriers
to prescribing contraception.102-104 State practice laws,
workflow design, and perceived barriers by pharmacists will
need to be addressed to fully expand patient access to
pharmacist-prescribed hormonal contraception.
Point-of-care testing
Point-of-care (POC) testing, such as blood glucose,
hemoglobin A1c, cholesterol and international normalized
ratio testing are some of the available community
pharmacist-provided services and may be included under a
CPA. In order to perform POC tests, pharmacies must
obtain a certificate of waiver from CMS to perform a
Clinical Laboratory Improvement Amendment (CLIA)105
waived test. A CLIA-waived test is designed for screening,
monitoring, or diagnosis outside of a laboratory setting and
are used within a community pharmacy setting.106
In recent years, POC testing has expanded beyond glucose
and cholesterol (Table 2). Community pharmacists
providing POC testing for group A streptococcus and
influenza under a CPA increased access by administering
POC tests outside of normal clinic hours, conducting tests in
patients without a primary care provider, and providing
appropriate medication based on test results.107-109
Similarly, POC testing for human immunodeficiency virus
and hepatitis C was provided by trained community
pharmacists.110-112 The availability of these tests is not
widespread and patient awareness, willingness to receive,
and payment mechanisms for community-based POC
infectious disease testing remain a concern.113 While POC
testing may be an important means to screen patients and
provide care, the business model for it must be developed.
Opioid reversal agents
In response to the opioid epidemic in the US, efforts to
increase access to naloxone in community pharmacies have
been widespread. Each state and the District of Columbia
has varying levels of how pharmacists may prescribe or
dispense naloxone, ranging from a statewide protocol,
including pharmacist prescribing authority, to the ability to
Table 2. Point-of-care tests available in community pharmacy in
the United States*
Blood glucose
Cholesterol
Group A Streptococcus
Helicobacter pylori
Hemoglobin A1c
Hepatitis C Virus
Human Immunodeficiency Virus
Influenza
International Normalized Ratio
Pharmacogenetics
*Note that this is not a complete list of all possible tests.
105
Adapted from information provided by NCPA and previous
114, 115
literature.

dispense without a prescription.116,117 In the 2019 National
Pharmacist Workforce Study, 72.2% participants reported
dispensing naloxone.66 Despite 57% pharmacists working in
community settings feeling confident recommending
naloxone, only 28.3% felt confident administering it.66 A
greater proportion of mass merchandiser (76.6%) and large
chain (63.3%) pharmacies dispense naloxone via a standing
order compared to independent and small chain
pharmacies. The latter dispense naloxone more frequently
based on a prescription order (44.4% each).66
An analysis of community pharmacy records revealed that
naloxone dispensing increased from 1,282 prescriptions
(0.4 per 100,000) in 2012 to 556,847 (170.2 per 100,000) in
2018. Individuals with commercial insurance represented
the largest percentage of dispensed naloxone prescriptions
in 2018 (51.1%), followed by Medicare (35.9%), Medicaid
(10.7%), and self-pay (2.4%). A majority (42.3%) of
prescriptions did not require out-of-pocket costs, while
24.5% required out-of-pocket costs of less than USD 10.00,
21.9% between USD 10.01–50.00, and 5.8% over USD
50.00. Counties with high naloxone-dispensing also had
more high-dose opioid dispensing rates, higher drug
overdose deaths rates, higher potential buprenorphine
treatment capacity, and higher rates of Medicaid
enrollment. Micropolitan and rural counties were less likely
to be a high naloxone-dispensing county compared to
metropolitan ones. However, in this study, pharmacists
were grouped under “other” specialty prescribers, thus
limiting the ability to determine the amount of pharmacistprovided naloxone.118 Differences in state practice laws,
required pharmacist training, pharmacist time, pharmacist
confidence in naloxone prescribing, inadequate pharmacist
reimbursement, and patient out-of-pocket costs present
current challenges to widespread adoption of naloxone
dispensing.119,120
Smoking cessation
Prescription of tobacco cessation therapy can be achieved
through the establishment of population-based CPAs,
standing orders, statewide protocols, or independent
prescribing. In the latter two cases, pharmacists not only
prescribe but are also able to bill the patient’s insurance for
any covered smoking cessation services in addition to the
prescription medication dispensed (reimbursement
variable).121 For example, in California, the Medicaid
program (Medi-Cal) covers smoking cessation services at
85% of the physician’s fee.99 The products covered under
statewide protocols vary across states, with some including
varenicline and bupropion, in addition to non-prescription
and prescription nicotine replacement therapy products.
Pharmacists must meet minimum education requirements
to engage in autonomous prescribing of tobacco cessation
products.122 Provision of this service is sporadic, despite
legislation being passed in many states.
FUTURE DIRECTIONS IN COMMUNITY PHARMACY
IN THE US
Community pharmacy practice in the US contains multiple
stakeholders whose interests often compete. To discuss the
future of community pharmacy in the US we will use
Donabedian’s structure, process, outcomes framework.123
Structure
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One of the most significant barriers is the current payment
structure and pharmacists not being recognized as
providers by CMS, as discussed above. While achieving
provider status is an important step for the profession to
bill under fee-for-service, it is also important to
acknowledge a growing shift from this model to pay-forperformance healthcare reimbursement. Similar to other
jurisdictions around the world, the US is facing precipitous
increases in healthcare costs. One method for beginning to
address these increases is shifting incentive structures
away from the quantity of services provided to one focused
on the quality of services provided. Quality measures have
been proposed and adopted at multiple levels of the
healthcare system including hospitals, physicians, nursing
homes and health plans, to drive improvement, inform
consumers, and determine payment. Of particular
relevance to community pharmacy is the Medicare Star
Ratings program which evaluates the quality of Medicare
prescription drug plans on a 5-star system where higher is
better.124 There are currently five active medication-related
measures, which have been developed in collaboration
with the Pharmacy Quality Alliance, whose mission is to
optimize health by advancing quality medication use.125 The
five measures are: 1) medication adherence (via calculation
of the proportion of days covered) for 1a) diabetes, 1b)
hypertension, and 1c) cholesterol medications; 2) CMR
completion rate as part of the MTM program; and 3) statin
use in persons with diabetes.126,127 Though not specific to
community pharmacy, community pharmacists have the
potential to impact all these measures through many of the
services outlined previously. Importantly, health plans in
select states have started paying bonuses to high
performing pharmacies (i.e., those who positively impact
medication-related quality measures) and including them in
preferred pharmacy networks, meaning that patients who
utilize these pharmacies will have reduced or no co-pays for
their
prescriptions.128
Although
value-based
reimbursement continues to evolve, it does present
community pharmacy with a unique opportunity to build a
new community pharmacy practice model.
Another significant barrier, but also a potential
opportunity, comes from needed improvements in access
to technologies such as EHRs, use of mobile health
applications, and telemonitoring.129,130 Success in accessing
patients’ EHRs from a community pharmacy setting to help
coordinate care and communicate with other providers is
achievable, though would require collaborations across
multiple health systems and EHRs.131 Access to EHRs helps
community pharmacists gain access to the current
medication list, doses, and laboratory results to monitor
medication effectiveness and disease control or
progression.132 The use of mobile health apps for sharing of
health information between the community pharmacy, the
patient, and other healthcare providers is growing. For
instance, the MEDIvate iOS smartphone application using
cloud architecture allows patients to scan a vaccine
prescription QR code to import their vaccine data and
vaccine information into the app.133
Failing to adequately address these barriers will leave
community pharmacy open to a substantial threat from
disruptors such as Amazon. In addition to its recent
acquisition of the online pharmacy PillPack, Amazon’s

operations are specifically designed for efficiency, have
extensive transportation networks, and can leverage the
presence of Whole Foods (a groceries store) to provide
great customer experience.134,135 Amazon can offer
substantial discounts to cash-paying customers because of
its size and will present a viable alternative to the
employers searching for pharmacy benefit plans for their
employees.134 Finally, it is also nearly prepared to meet the
needs of the Drug Supply Chain Security Act, which will
come into effect in 2023, that requires that all prescription
medications be traceable from manufacturer to patient.134
Process
The success of structural adaptations will only be achieved
if corresponding adjustments are made to processes taking
place within the community pharmacy. To begin, all
technical duties should be transitioned to pharmacy
technicians. There is growing evidence supporting
technicians’ participation in MTM sessions, serving as
pharmacist extenders, and completing tech-check-tech
dispensing.136,137 Some states have passed legislation
allowing technicians to provide some immunizations.138
Before these tasks can be given entirely to technicians, the
laws governing technician practice across the country must
be standardized to ensure adequate levels of training and
competency.137
The COVID-19 pandemic has also further accelerated the
process of giving and receiving care via telehealth.139 This
represents an opportunity for community pharmacy to
transition some services to this delivery format to save
patients time and pharmacy resources. For example, it
could be a means to standardize the provision and increase
uptake of MTM among Medicare Part D plan beneficiaries.
As technicians release pharmacists’ time for clinical duties
and new opportunities for the provision of care via
telehealth are adopted, the profession should acknowledge
and lessen the impact of “community pharmacy practice
inertia”, characterized by a reliance on outdated protocols
and practices in the face of new evidence.140 Despite
various legislative advances, uptake of community
pharmacist services is generally low across states, speaking
further to the need to address both structure and process
aspects.
Outcome
Once structure and process adjustments have been made,
community pharmacists can focus on service expansion and
clinical, humanistic and economic outcomes. A common
criticism to the pharmacy practice literature relates to the
poor and inconsistent intervention reporting.141-144 As
mentioned above, a challenge with MTM and medication
synchronization is the lack of standardized definitions and
process of how these services are provided across multiple
studies.82,83,92 In order for services to be integrated in
routine community pharmacy practice and sustained over
time, it will be helpful to draw from the implementation
science discipline. Implementation science focuses on
methods to “promote the systematic uptake of research
findings and other evidence-based practices into routine
practice”.145
Implementation
science
emphasizes
systematic thinking about healthcare delivery and has
developed numerous frameworks for, not only rethinking
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practice change implementation, but also for guiding
ongoing data collection and monitoring.146 These data will
be as equally important as patient outcomes as current and
future practice scope expansion legislation is passed.
CONCLUSION
Community pharmacy is the US offers some clinical services
to support primary care, but the business model retains a
focus on dispensing. Chain pharmacies (and potentially
pharmacies within CPESN) offer important opportunities to
scale clinical services nationwide. Yet, the delivery of
medications to homes via incredibly efficient modes –
whether Amazon or automated transportation – offers
significant opportunity beyond dispensing for helping

healthcare providers and patients obtain the best
outcomes from medications. When we overcome structural
barriers to care such as limited reimbursement and lack of
coordination with the EHR, then community pharmacists
will be able to adapt their processes of care to achieve
improved patient outcomes.
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